Lenzilumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Lenzilumab
Accession Number
DB15148
Description

Lenzilumab is under investigation in clinical trial NCT02546284 (Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)).

Type
Biotech
Groups
Investigational
Purchasing individual compounds or compound libraries for your research?
Learn More
Synonyms
Not Available

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
IE4X6497XK
CAS number
1229575-09-0

References

General References
Not Available
Wikipedia
Lenzilumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Not Yet RecruitingTreatmentMalignancies / Novel Coronavirus Infectious Disease (COVID-19) / Respiratory Viral Infections1
3RecruitingTreatmentCoronavirus Disease 2019 (COVID-19) Pneumonia / Novel Coronavirus Infectious Disease (COVID-19)1
2RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
1CompletedTreatmentChronic Myelomonocytic Leukemia (CMML)1
1, 2RecruitingTreatmentRelapsed/Refractory Large B-cell Lymphoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 08:54 / Updated on June 12, 2020 10:53

Pm 3